VTGN - ビスタジェン・セラピュ―ティクス (VistaGen Therapeutics Inc.)

VTGNのニュース

   Nasdaq Grants VistaGen 180-Day Extension to Meet Minimum Bid Price Requirement  2020/10/14 12:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Company received written…
   VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering  2020/08/10 12:30:00 PR Newswire
SAN FRANCISCO, Aug. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the underwriters of its previously announced…
   VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering  2020/08/05 20:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its previously…
   VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration  2020/08/04 12:00:00 PR Newswire
/PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression…
   VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock  2020/08/03 00:00:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Aug. 2, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten…
   VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering  2020/08/10 12:30:00 PR Newswire
SAN FRANCISCO, Aug. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the underwriters of its previously announced…
   VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering  2020/08/05 20:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its previously…
   VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration  2020/08/04 12:00:00 PR Newswire
/PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression…
   VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock  2020/08/03 00:00:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Aug. 2, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten…
   VistaGen Therapeutics Announces Proposed Public Offering of Common Stock  2020/07/31 20:18:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., July 31, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced it has commenced an underwritten…
   VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia  2020/06/25 12:00:00 PR Newswire
/PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression…
   VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview  2020/02/13 21:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financial…
   VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients  2020/01/30 13:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced that its…
   VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans  2019/12/19 13:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Dec. 19, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, and Baylor College of…
   VistaGen Up on Fast Track Designation for Anxiety Disorder Drug  2019/12/11 09:06:00 Zacks Investment Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.

calendar